Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

T he FDA issued an approval of Novavax’s COVID-19 vaccine, but with unusual restrictions, Lauran Neegaard of AP News reports. The FDA recently granted the company full approval ...

CHICAGO, April 24 (Reuters) - Thousands of Americans campaigning for the Novavax (NVAX.O), opens new tab COVID-19 booster got some good news this week: the FDA signaled it might still win approval ...

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The COVID-19 vaccine maker reported an earnings per share of $2.93 ...

The COVID-19 vaccine maker reported an earnings ... President and Chief Executive Officer, Novavax. "We remain focused on creating shareholder value as we advance our three priorities for the ...

WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus ...

showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's vaccine. This positive announcement aligns with a 17.8% increase in the company's share ...